Skip to content

Evaluation of mediVR-KAGURA Guided Therapy

Evaluation of mediVR-KAGURA Guided Therapy: A Prospective Interventional Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04562662
Enrollment
20
Registered
2020-09-24
Start date
2020-09-01
Completion date
2022-03-31
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction, Physical Disability

Keywords

Virtual Reality, Physical, Cognitive

Brief summary

The objective is to evaluate mediVR-KAGURA guided therapy for the treatments of physical and cognitive dysfunctions regardless of baseline disease in a prospective interventional design.

Detailed description

The patients sit on an upright chair, wear a head-mounted display (HMD) and grab two handheld controllers in a motion-tracked three-dimensional space called room scale of the mediVR-KAGURA (mediVR, Inc. Toyonaka City, Osaka, Japan). mediVR-KAGURA can provide users with \>90 frames per second (fps) graphic operation with an approximately 110° viewing angle and accurate three-dimensional tracking technology. First, we evaluate conventional and maximum reaching distances at 0°, 45°, and 90° level surface for the left hand (0L, 45L, 90L) and at 90°, 135°, and 180° level surface for the right hand (90R, 135R, or 180R) for calibration in a sitting position. During rehabilitation, patients are instructed to touch a fixed objects or catch a falling objects at the pre-specified height and distance levels in each degree. Horizontal distances were classified into three categories, namely long, middle, and short which were calculated using the following formulas: 0.9 \* maximum reaching distance, 0.9 \* (conventional + maximum reaching distances)/2, and conventional reaching distance respectively. A falling object disappeared at a 20 cm height for safety if the patients missed to catch it. The purpose of reaching hands was to stimulate and break down body trunk balance, and to train participants to balance for stable walking. By thinking about the timing and distance and recognizing the next targets repeatedly, cognitive function was simultaneously stimulated for dual-task training. The 7 parameters of the rehabilitation programs can be set like as follows: (1) distance (short, middle or long), (2) direction (0L, 45L, 90L, 90R, 135R, or 180R), (3) height of object, (4) size of object (center or outline), (5) size of sensing sphere of the controller, (6) falling speed of the square box (from 0 to 300 cm/s), and (7) intervals for each task. Participants first underwent practical programs to familiarize themselves with mediVR-KAGURA guided rehabilitation, followed by rehabilitation programs. Provision of the rehabilitation programs will be personalized.

Interventions

DEVICEmediVR KAGURA

Approximately 20 min mediVR KAGURA-guided rehabilitation

Sponsors

Japan Society of Clinical Research
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 110 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with physical and/or cognitive dysfunctions 2. Agreed to the participation of this study with written informed consent by themselves or guardians

Exclusion criteria

1\. Inappropriate candidates at attending physician's discretion

Design outcomes

Primary

MeasureTime frameDescription
Change in Timed up and go testbaseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the interventionThe Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. Shorter score means a better outcome. The minimum value could be 5 seconds or less, and the maximum value could be infinity (cannot complete the test).
Change in Trail Making Testbaseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the interventionThe Trail Making Test (TMT) is a neuropsychological test of visual attention and task switching. Shorter score means a better outcome. The minimum value could be 15 seconds or less, and the maximum value could be infinity or be defined as 300 seconds when patients cannot complete the test.

Secondary

MeasureTime frameDescription
Changes in Functional Independence Measurebaseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the interventionThe Functional Independence Measure (FIM) is an assessment tool that aims to evaluate the functional status of patients throughout the rehabilitation process following a stroke, traumatic brain injury, spinal cord injury or cancer. Higher score means a better outcome. The minimum value is 18, and the maximum value is 126.
Changes in Berg balance scalebaseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the interventionThe Berg Balance Scale (or BBS) is a widely used clinical test of a person's static and dynamic balance abilities. Higher score means a better outcome. The minimum value is 0, and the maximum value is 56.
Changes in Mini Mental State Examinationbaseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the interventionThe Mini-Mental State Examination (MMSE) test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Higher score means a better outcome. The minimum value is 0, and the maximum value is 30.
Changes in Self Rating Depression Scalebaseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the interventionThe Self Rating Depression Scale (SDS) is a psychiatric measuring instrument having descriptive words and phrases that indicate the severity of depression for a time period. Lower score means a better outcome. The minimum value is 20, and the maximum value is 80.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026